

1 **Based on breast CEUS parameters combined with**
2 **serum CA153, a nomogram model was constructed to**
3 **predict the molecular classification of breastcancer**
4

5 Yanlei Ji¹, Zhen Han², Yong Zhang³, Wenwen Sun^{1*},

6

7 ¹Department of Ultrasound Medicine, Shandong Cancer Hospital and Institute,
8 Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,
9 Shandong Province 250117, China

10 ²Department of Internal Medicine, Jinan Second People's Hospital, Jinan, China. Jinan,
11 Shandong Province 250022, China

12 ³Department of Radiation Oncology , Shandong Cancer Hospital and Institute,
13 Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,
14 Shandong Province 250117, China

15

16 *Corresponding author: Wenwen Sun

17 telephone number : 18206413312

18 E-mail: sunwenwen419@163.com

19 Current Address: Shandong Cancer Hospital and Institute, Shandong First Medical
20 University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan,
21 Shandong

22

23

24

25

26

27

28

29 **Abstract**

30 Objective: To analyze the role of contrast-enhanced ultrasound (CEUS)
31 parameters combined with serum tumor marker CA153 in the prediction of Breast
32 Cancer (BC) molecular typing. Methods: From January 2020 to January 2023, 120
33 BC patients diagnosed in our hospital were studied. According to the pathological
34 results, the patients were divided into Luminal and non-Luminal BC groups. Both
35 groups underwent contrast-enhanced ultrasound. The time-intensity curve (TIC) is
36 obtained, and the relevant characteristic parameters are obtained, including peak
37 intensity (PI), peak time (TTP), area under the curve (AUC), and mean transit time
38 (MTT). Serum tumor marker CA153 was detected in both groups. Combined with
39 CEUS characteristic parameters and serum CA153 of two groups of BC patients, a
40 multiple Logistic regression model was constructed, and a nomogram prediction model
41 was constructed based on the model. Calibration curve and receiver operating
42 characteristic (ROC) curve were used to analyze the value of this model in the
43 prediction of BC molecular classification. Results: There were no significant
44 differences between Luminal BC patients and non-Luminal BC patients in clinical
45 parameters and qualitative parameters of contrast-enhanced ultrasound, while there
46 were statistical differences between quantitative parameters PI, AUC and serum tumor
47 marker CA153. The AUC of the combined diagnosis of three parameters (PI, AUC and
48 CA153) was significantly higher than that of the single index diagnosis group. The
49 ROC curve AUC of BC molecular typing was predicted to be 0.94 based on the three-
50 parameter nomogram, and the fitting of the actual curve and the ideal curve in the

51 calibration curve was close. Conclusions: The nomogram model based on breast
52 contrast-enhanced ultrasound (CEUS) parameters combined with serum CA153 can
53 effectively predict the molecular classification of BC.

54 **Keyword:** Breast Cancer, CEUS, ROC, CA153

55

56 **Introduction**

57 Breast Cancer (BC) is one of the most common malignant tumors in wom
58 en. In recent years, its incidence has been increasing year by year and showing
59 a trend of youth, and seriously threatening the life health and quality of life of
60 patients^[1]. BC is a hormone-dependent tumor, and its carcinogenic risk is close
61 ly related to estrogen imbalance^[2-4]. Estrogen is mediated by estrogen receptor
62 (ER) and progesterone receptor (PR) and its expression level is different in dif
63 ferent BC patients, and its clinical manifestations, treatment and prognosis are
64 also different^[5, 6]. Based on the expression status of ER and PR, BC is divided
65 into Luminal type (positive for either ER or PR, including Luminal A and Lu
66 minal B) and non-Luminal type (negative for both ER and PR, including HER
67 -2 and TN)^[7]. Therefore, the development of accurate diagnostic methods for B
68 C patients with different molecular subtypes is very important for the treatment
69 and prognosis of patients^[8]. In recent years, with the development of molecular
70 biology technology, more tumor molecular markers related to BC have been di
71 scovered. Evaluating the expression levels of these markers in the serum of pat
72 ients can provide valuable information for the occurrence, invasion and metasta

73 sis of BC^[9]. Studies have suggested that carbohydrate antigen 153 (CA153), c
74 arcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) have ce
75 rtain clinical value for BC screening, postoperative follow-up, recurrence and m
76 etastasis, especially CA153, which is the most valuable single diagnostic index
77 with the best sensitivity, accuracy, positive predictive value and specificity^[10].
78 However, CA153 alone cannot accurately reflect the overall situation of the les
79 ion. contrast-enhanced ultrasound (CEUS), as a non-invasive imaging technique,
80 can observe the microcirculation in BC lesions. At the same time, it can fully
81 reflect the information of the internal and peripheral tissue structure of the lesi
82 on^[11]. Based on this, the present study constructed a nomogram diagram with
83 CEUS parameters combined with serum tumor marker index CA153 to predict
84 different BC molecular typing, with a view to providing clinical reference for
85 precise diagnosis and personalized treatment of BC.

86

87 **Materials and methods**

88 **1.1 Patients**

89 01/09/2024 searched the HIS information of our hospital, and selected 120 breast cancer
90 patients diagnosed by examination from January 2020 ~ January 2023 as the research
91 subjects. All patients underwent ultrasonography and clinical immunohistochemical
92 pathology. Inclusion criteria: Invasive BC was confirmed by needle biopsy and
93 immunohistochemical evaluation was performed; No chronic diabetes mellitus;

94 Patients volunteered to participate in the study; Complete medical records. Exclusion
95 criteria: serious cardiovascular and cerebrovascular diseases and digestive tract
96 diseases; Hypertension and autoimmune disease; Pregnancy or breastfeeding;
97 Allergic to ultrasound contrast agent. This study was approved by the Ethics Committee
98 of our hospital, and all patients have signed informed consent.

99 **1.2 Contrast-enhanced ultrasound**

100 GE Logiq E9 color Doppler ultrasonic diagnostic instrument, ML6-15 probe, frequency
101 9~15 MHz; Equipped with contrast-enhanced ultrasound imaging software. First,
102 routine ultrasound was performed to observe the conditions of both mammary glands
103 and determine the location of breast lesions to obtain better two-dimensional images.
104 The optimal section was selected to cut into the angiography state, and 2.4 ml Sonovi
105 (Bracco, Italy) was injected rapidly through the cubitus vein, and then rinsed with 5.0
106 ml 0.9% normal saline. The dynamic perfusion process of breast lesions was observed
107 and recorded. The region of interest (diameter 4 mm, area 8 mm²) was selected when
108 the breast lesions reached the peak of enhancement, and 5 points were selected from
109 the inside and the edge of the lesions as the region of interest. The measured values of
110 the region of interest at a total of 10 points were recorded and their mean values were
111 taken. Start the QLAB analysis software to automatically analyze and obtain the time-
112 intensity curve (TIC), and perform curve fitting to obtain the blood flow parameters of
113 the region of interest: peak intensity (PI), peak time (TTP), area under the curve (AUC)
114 and mean transit time (MTT). The above images were analyzed by two physicians. If

115 there were any differences in the diagnosis results, the third physician would participate
116 in the discussion and get the final result after reaching an agreement.

117 **1.3 Immunohistochemical examination**

118 The expression levels of ER, PR, HER-2 and Ki-67 were detected in all BC samples
119 after paraffin embedding and SP staining. ER, PR Rubric^[12]: ER and PR positive tumor
120 nuclei $\geq 1\%$ positive, $< 1\%$ negative. HER-2 Rubric^[13]: Negative 1+ is HER-2 negative
121 and 3+ is HER-2 positive; those with 2+ need to be tested by fluorescence in situ
122 hybridization, in which those with gene amplification are HER-2 positive and those
123 without amplification are HER-2 negative. Ki-67 proliferation index^[12]: Select the
124 area with the highest staining density of tumor cells, and count the staining of 1000
125 cells. The number of positive cells/total cell count is the Ki-67 proliferation index.

126 **1.4 CA153 detection and judgment criteria**

127 2 mL of fasting venous blood was collected from both groups of patients in the early
128 morning, and then centrifuged at 3000 r/min for 10 min after self-coagulation to
129 separate the serum, which was stored in the refrigerator at -20°C for examination. Serum
130 CA153 concentration was detected by using Abbott Architect 2000 automatic
131 chemiluminescence immunoassay analyzer and special reagents. All operations were
132 performed in strict accordance with the instrument and reagent instructions. The critical
133 value of CA153 was 31.3 U/mL, and the assay was considered positive if the value
134 exceeded the critical value.

135 **1.5 Data analysis**

136 All analyses were performed using R software version 4.0.2. Logistic regression and
 137 ROC analysis using R software. Measurement information data were expressed as
 138 Mean±SD and one-way ANOVA was used for comparison between groups. Count data
 139 data were expressed as frequencies and χ^2 test was used. Receiver operating
 140 characteristic curves (ROC) were used to analyze the diagnostic performance of the
 141 model for different BC subtypes. $P<0.05$ was statistically significant.

142

143 **Results**

144 **2.1 Clinical characteristics**

145 The 120 study patients ranged in age from 24 to 80 years. There were 72
 146 patients with Luminal BC and 48 patients with non-Luminal BC. The general
 147 data of the study patients included age, maximum mass diameter, menopause,
 148 pathological type, and pathological grade, and the results were shown in Table
 149 1. There was no significant difference in the general data of 120 patients with
 150 different BC types.

151

152 **Table 1 Clinical characteristics**

| Molecular type | Age (years, mean±SD) | Maximum diameter (mm, mean±SD) | Menopause | | Pathological type | | Histological grade | | |
|----------------|----------------------|--------------------------------|-----------|-----|---------------------------|----------------------------|--------------------|----|-----|
| | | | N | Yes | invasive ductal carcinoma | invasive lobular carcinoma | I | II | III |
| | | | | | | | | | |

| | | | | | | | | | |
|-------------|------------|------------|-------|----|--------|----|-------|----|----|
| Luminal | 52.68±10.0 | 22.57±9.56 | 55 | 17 | 48 | 12 | 12 | 45 | 18 |
| | 1 | | | | | | | | |
| Non-Luminal | 52.0±10.15 | 24.30±7.76 | 32 | 16 | 41 | 2 | 5 | 31 | 10 |
| χ^2/t | 0.3626 | 1.044 | 1.365 | | 0.1950 | | 0.059 | | |
| <i>P</i> | 0.7175 | 0.2985 | 0.243 | | 0.9071 | | 0.808 | | |

153

154 **2.2 CEUS manifestations**

155 The results of comparing the qualitative parameters of ultrasonography in patients
 156 with different BC subtypes are shown in Figure 1 and Table 2. In patients with the
 157 Luminal type, ultrasonography is dominated by centripetal hyperenhancement, with a
 158 predominantly rapid ascending and slow descending enhancement pattern, and unclear
 159 and enlarged enhancement with radiolucent convergence of the borders; Centripetal
 160 enhancement accounted for 14/39 patients with the non-Luminal type, with a
 161 predominantly rapid ascending and slow descending pattern of enhancement, unclear
 162 and enlarged borders after enhancement, and radiolucent convergence of the borders.

163

164 **Figure 1 Contrast-enhanced ultrasound of different molecular types of BC**

165 (A: Ultrasonography of a patient with Luminal B BC showing radial convergence around the periphery of the mass
 166 on ultrasonography; B: Ultrasonography of a patient with TN BC showing a well-defined and well-formed lesion
 167 on ultrasonography)

168

169

170 **Table 2 Contrast-enhanced ultrasound findings of patients with different BC types**

| Molecular type | Enhanced intensity | | | Enhancement sequence | | | enhancement mode | | | Enhanced | Radial | Enhanced | Perfusion | | | | |
|----------------|--------------------|-----|------|----------------------|----------|-------------|------------------|--------------|---------|----------|--------|----------|-----------|---------|----|--------|----|
| | Equ | low | high | off-center | disperse | slow growth | Rapid growth | Rapid growth | Unclear | Unclear | Range | Defect | | | | | |
| Luminal | 18 | 15 | 39 | 17 | 32 | 23 | 12 | 56 | 4 | 14 | 58 | 49 | 2 | 19 | 53 | 44 | 28 |
| Non-luminal | 8 | 1 | 39 | 7 | 14 | 27 | 8 | 36 | 4 | 22 | 26 | 28 | 2 | 27 | 21 | 30 | 18 |
| χ^2 | 12.1607 | | | 11.9245 | | | 4.8137 | | | 10.4762 | | 13.0319 | | 14.6953 | | 5.3785 | |
| <i>P</i> | 0.058 | | | 0.063 | | | 0.5679 | | | 0.0649 | | 0.054 | | 0.062 | | 0.1460 | |

171

172 **2.3 Comparison of CEUS characteristic parameter and**
 173 **CA153**

174 The CEUS quantitative parameters and serum CA153 indexes of patients
 175 with different BC types were compared, The results are shown in Table 3. Th

176 ere were significant differences in PI, AUC and serum CA153 between Lumina
177 l and non-Luminal BC patients.

178

179 **Table 3 Comparison of CEUS characteristic parameter and CA153**

| Molecular type | PI(%) | TP(s) | AUC(%s) | MTT(s) | CA153(U/mL) |
|----------------|-----------|-----------|--------------|-----------|--------------|
| Luminal | 37.50±2.2 | 23.18±2.2 | 1576.11±272. | 31.42±4.6 | 111.18±43.86 |
| Non-Luminal | 44.53±7.1 | 23.55±4.2 | 1907.74±340. | 32.42±5.2 | 84.57±39.30 |
| t | 6.600 | 0.541 | 5.961 | 1.112 | 3.401 |
| P | <0.001 | 0.589 | <0.001 | 0.269 | <0.001 |

180

181 **2.4 Binary logistic regression analysis screened the** 182 **independent predictors of BC molecular typing**

183 To further evaluate the predictive performance of serum tumor marker CA153 and
184 contrast-enhanced ultrasound parameters in different types of BC. Univariate
185 regression analysis was performed to compare the clinical data, CEUS quantitative
186 parameters and serum tumor marker CA153 between Luminal and non-Luminal
187 subtypes. Subsequently, univariate factors with P values < 0.05 were included in the
188 multivariate regression analysis, including CEUS parameters PI, AUC and serum tumor

189 marker CA153. Multivariate logistic regression analysis showed that PI, AUC and
 190 CA153 were independent predictors of BC molecular typing ($P < 0.05$). (Table 4).

191 **Table 4 Binary logistic regression analysis screened the independent predictors of**
 192 **BC molecular typing**

| Variate | Univariate regression analysis | | | Multivariate regression analysis | | |
|----------------------|--------------------------------|-----------|-------|----------------------------------|-------|---|
| | OR | 95%CI | P | OR | 95%CI | P |
| Age | 0.99 | 0.96,1.03 | 0.715 | - | - | - |
| Menopause | 1.47 | 0.65,3.33 | 0.355 | - | - | - |
| Maximum diameter | 1.02 | 0.98,1.07 | 0.297 | - | - | - |
| Histological grade | 0.79 | 0.33,1.90 | 0.597 | - | - | - |
| Enhanced intensity | 2.25 | 0.88,5.78 | 0.092 | - | - | - |
| Enhancement sequence | 2.73 | 0.97,7.71 | 0.058 | - | - | - |
| enhancement mode | 1.50 | 0.29,7.81 | 0.630 | - | - | - |

| | | | | | | |
|------------------------|------|-----------|---------|------|-----------|-------|
| Enhanced post-boundary | 0.29 | 0.13,0.64 | 0.103 | - | - | - |
| Radial convergence | 1.52 | 0.71,3.25 | 0.278 | - | - | - |
| Enhanced range | 0.58 | 0.13,0.60 | 0.215 | - | - | - |
| Perfusion defect | 0.99 | 0.96,1.03 | 0.087 | - | - | - |
| PI | 1.36 | 1.20,1.53 | < 0.001 | 1.31 | 1.09,1.58 | 0.004 |
| TP | 1.04 | 0.92,1.16 | 0.542 | - | - | - |
| AUC | 1.01 | 1.01,1.01 | < 0.001 | 1.01 | 1.01,1.01 | 0.002 |
| MTT | 1.04 | 0.97,1.13 | 0.269 | - | - | - |
| CA153 | 0.98 | 0.98,0.99 | 0.002 | 0.98 | 0.96,0.99 | 0.001 |

193

194 **2.5 Construction of nomogram prediction model and**
 195 **comparative analysis of prediction efficiency**

196 Based on the independent predictors (PI, AUC, CA153) of the three molecular
197 subtypes of BC screened by binary logistic regression analysis, ROC curve was
198 established to evaluate the accuracy of the combination of the three parameters in
199 predicting non-Luminal BC (Figure 1). The results showed that the area under the curve
200 (AUC) of the three-parameter model was 0.8307 (95%CI: 0.7437-0.9177), the
201 sensitivity and specificity of the prediction were 75% and 94.44%, respectively, and
202 the cut-off value of the prediction model was 0.3437. This indicates that the three-
203 parameter combined prediction model of PI, AUC and serum CA153 has good
204 predictive performance for the diagnosis of non-Luminal events (Table 5). Finally, we
205 constructed a nomogram to predict the probability of non-Luminal BC based on the PI,
206 AUC, and CA153 mentioned above (Figure 2). Each independent variable value
207 corresponds to a score in the top row, and the scores of the individual independent
208 variables are summed to obtain the total score, from which the probability is
209 subsequently calculated. Finally, we used ROC curve and calibration curve to evaluate
210 the predictive performance of the nomogram (Figure 3,4). The AUC of ROC curve was
211 0.94 (95%CI: 0.90-0.98). In the calibration curve, the actual curve was very close to
212 the ideal curve. The nomogram has good predictive value for predicting the risk of non-
213 Luminal BC.

214

215 **Figure2 ROC curve was predicted by three-parameter combination**

216

217 **Table 5 Comparison of AUC values**

| | AUC | 95%CI |
|----------|--------|---------------|
| PI | 0.8098 | 0.7163-0.9032 |
| AUC | 0.7590 | 0.6701-0.8478 |
| CA153 | 0.6780 | 0.5799-0.7760 |
| Combined | 0.8307 | 0.7437-0.9177 |

218

219 **Figure 3 ROC curve of the nomogram model**

220

221 **Figure 4 Calibration curve of nomogram model**

222

223 **Discussion**

224 BC is a highly vascular heterogeneous and malignant stromal tumor, and its
225 incidence is increasing year by year, which has become the first disease seri-
226 ously endangering women's health^[14]. The etiology of the disease is still unclear,
227 and genetic factors and estrogen endocrine abnormalities are the main causes
228 of the disease^[15]. In 2000, Perou et al^[16] first proposed that BC has different
229 molecular subtypes, which can be divided into Luminal type and non-Luminal
230 type (including HER-2 type and TN type). Studies have found that different m-
231 olecular subtypes of BC have different biological behaviors, chemotherapy sensi-
232 tivity and prognosis. Among them, Luminal BC is the most common molecular
233 subtype, accounting for about 50%-70% of BC including Luminal A and Lumi-
234 nal B subtypes. Non-Luminal BC includes two different subtypes, HER-2 and
235 TN subtypes, and this molecular subtype of BC is highly heterogeneous and c-
236 haracterized by high invasiveness. Compared with Luminal BC, it is more diffi-

237 cult to diagnose and treat. Therefore, early detection, early diagnosis and early
238 treatment of different molecular subtypes of BC are of great significance for i
239 mproving the survival rate and quality of life of patients.

240 The occurrence, development, invasion and metastasis of BC are dependent
241 on neovascular vessels. The marginal zone of tumor is an area with vigorous
242 growth of tumor cells. The blood vessels are dense and densely distributed, an
243 astomosing with each other to form loops, and some blood vessels are dilated
244 in sinus shape^[17]. CEUS, as a non-invasive imaging method for preoperative ev
245 aluation of tumor angiogenesis, can accurately display blood perfusion compared
246 with conventional ultrasound. The application of contrast-enhanced ultrasound c
247 an not only clearly observe the course and distribution of microvessels in the t
248 umor, but also provide quantitative analysis of the tumor, providing imaging re
249 ference for the preoperative diagnosis and treatment of BC^[18]. In this study, we
250 compared the characteristics of contrast-enhanced ultrasound between the two gr
251 oups of patients. We found that the contrast-enhanced ultrasound of Luminal B
252 C showed high enhancement, unclear boundary, radial convergence around the
253 periphery, and expanded range after enhancement, and the enhancement pattern
254 was mostly rapid increase and slow decrease. This result is the same as that o
255 f Wang Xiaoyan et al^[19], and can be used as a sensitive sign of Luminal BC.
256 Non-Luminal BC showed high enhancement on contrast-enhanced ultrasound, an
257 d the boundary was basically unclear after enhancement, and the boundary did
258 not significantly expand after enhancement, similar to the imaging characteristic

259 s of benign tumors, which was rare in other molecular subtypes, highlighting t
260 he heterogeneity of this subtype. Whether the quantitative parameters of contras
261 t-enhanced ultrasound are correlated with the molecular subtypes of BC, many
262 studies have conflicting conclusions^[20]. Lin Yun^[21] believes that there is a cert
263 ain correlation between the quantitative parameters of contrast-enhanced ultrasou
264 nd in different molecular types of BC, and Jia Wanru^[22] believes that there is
265 no statistically significant difference in the quantitative parameters of contrast-e
266 nhanced ultrasound between different molecular types of BC. In this study, we
267 found that there were significant differences in PI and AUC of contrast-enhanc
268 ed ultrasound in patients with different BC subtypes, which may have guiding
269 significance for predicting different molecular types of BC.

270 At present, with the rapid development of genomics and molecular biology,
271 different molecular subtypes of BC can better reflect the biological behavior of
272 tumors. The detection of serum tumor markers can not only assist in diagnosis,
273 but also effectively predict the efficacy, outcome and acquired drug resistance.
274 CA153 is an antigen closely related to human breast malignant tumors. It was
275 first found in BC epithelial cells as a variant of the epithelial surface glycopro
276 tein of breast cells. When a cell undergoes cancerous transformation, the activa
277 tion of glycosyltransferases causes changes in cell surface sugars and enters the
278 blood with the tumor cells^[23]. It has obvious tumor specificity for BC and is of
279 great significance for the early diagnosis of BC. The level of its serum content
280 can be used as an index for the evaluation of the efficacy of BC^[24, 25], it is c

281 urrently clinically recognized as a more specific tumor marker for the diagnosis
282 of BC. In this study, we found that the serum CA153 level was significantly
283 higher in Luminal subtype patients than in non-Luminal subtype patients. There
284 fore, we hypothesized that the serum CA153 difference in different BC subtype
285 s combined with CEUS related parameters could help us to better predict the
286 molecular subtype of BC. Based on this, we used multivariate Logistic regressi
287 on to analyze the clinical data, contrast-enhanced ultrasound characteristic para
288 meters and serum CA153 of the two groups of patients. The results showed th
289 at the quantitative parameters of contrast-enhanced ultrasound PI, AUC and ser
290 um CA153 were independent predictors of BC molecular typing. The ROC cur
291 ve was used to compare the efficacy of PI, AUC, CA153 single parameters an
292 d the combination of three parameters in the diagnosis of BC molecular typing,
293 and the results showed that the AUC of the combination of three parameters
294 was significantly higher than that of each parameter. Then we constructed a no
295 mogram prediction model using three parameters, and evaluated the predictive
296 performance of the model using ROC curve and calibration curve. The results
297 of ROC curve and calibration curve showed that the nomogram had good pred
298 ictive value for the risk of non-Luminal BC.

299 In conclusion, the ultrasonographic features of BC can reflect the biologica
300 l characteristics of different BC molecular typing and are closely associated wit
301 h the serum tumor marker CA153. In this study, the ultrasonographic paramete
302 rs of PI, AUC and serum CA153 were used to construct a columnar graphical

303 model to effectively predict the molecular typing of BC, which can provide ce
304 rtain clinical references for accurate diagnosis and personalized treatment of BC.
305 However, this study is a single-center retrospective analysis with a limited sam
306 ple size, which did not explore the specific molecular typing of BC and lacked
307 external data validation, so it needs to be further improved.

308

309 **Author contributions**

310 Yanlei Ji, Zhen Han, and Yong Zhang: study design, data analysis and int
311 erpretation, and manuscript revision. Wenwen Sun: manuscript drafting. All the
312 authors of this study read and approved the final manuscript.

313

314 **Funding**

315 No funding was granted for this study.

316

317 **Competing interests**

318 Authors declare no competing interests.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337 **References**

- 338 [1] Zhi B, Yu J Q, Lv S Q. To establish a multi-parameter model to predict early triple-negativ
339 e breast cancer (TNBC)[J]. Radiologic Practice, 2021,36(8):1021-1025.DOI: 10.13609/j.cnki.1
340 000-0313.2021.08.014
- 341 [2] Burstein H J. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cance
342 r[J]. N Engl J Med, 2020,383(26):2557-2570.DOI: 10.1056/NEJMra1307118
- 343 [3] Clusan L, Le Goff P, Flouriot G, et al. A Closer Look at Estrogen Receptor Mutations in Br
344 east Cancer and Their Implications for Estrogen and Antiestrogen Responses[J]. Int J Mol Sci,
345 2021,22(2).DOI: 10.3390/ijms22020756
- 346 [4] Valko-Rokytovska M, Ocenas P, Salayova A, et al. Breast Cancer: Targeting of Steroid Hor
347 mones in Cancerogenesis and Diagnostics[J]. Int J Mol Sci, 2021,22(11).DOI: 10.3390/ijms22
348 115878
- 349 [5] Farcas A M, Nagarajan S, Cosulich S, et al. Genome-Wide Estrogen Receptor Activity in Br
350 east Cancer[J]. Endocrinology, 2021,162(2).DOI: 10.1210/endocr/bqaa224
- 351 [6] Derakhshan F, Reis-Filho J S. Pathogenesis of Triple-Negative Breast Cancer[J]. Annu Rev P
352 athol, 2022,17:181-204.DOI: 10.1146/annurev-pathol-042420-093238
- 353 [7] Rella R, Belli P, Giuliani M, et al. Automated Breast Ultrasonography (ABUS) in the Screen
354 ing and Diagnostic Setting: Indications and Practical Use[J]. Acad Radiol, 2018,25(11):1457-1
355 470.DOI: 10.1016/j.acra.2018.02.014
- 356 [8] Subramanian S, Keating N L. Delays in breast cancer diagnosis after a state policy limiting
357 Medicaid enrollment[J]. Cancer, 2017,123(17):3219-3221.DOI: 10.1002/cncr.30769
- 358 [9] Bidard F C, Hajage D, Bachelot T, et al. Assessment of circulating tumor cells and serum m
359 arkers for progression-free survival prediction in metastatic breast cancer: a prospective obser
360 vational study[J]. Breast Cancer Res, 2012,14(1):R29.DOI: 10.1186/bcr3114
- 361 [10] Li X, Xu Y, Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases[J]. Pro
362 g Mol Biol Transl Sci, 2019,162:265-276.DOI: 10.1016/bs.pmbts.2019.01.005
- 363 [11] Ji C L, Li X L, He Y P, et al. Quantitative parameters of contrast-enhanced ultrasound in br
364 east invasive ductal carcinoma: The correlation with pathological prognostic factors[J]. Clin H
365 emorheol Microcirc, 2017,66(4):333-345.DOI: 10.3233/CH-170251
- 366 [12] National Health Commission Of The, S Republic Of China. Breast Cancer Guidelines (2022
367 edition)[J]. China Licensed Pharmacist, 2022,19(10):1-26
- 368 [13] Liu Y P, Bu H, Yang W T. Chinese breast cancer HER2 detection guidelines update inter
369 pretatio (2019 edition)[J]. Chinese Journal of Pathology, 2019,48(3):182-185.DOI: 10.3760/c
370 ma.j.issn.0529-5807.2019.03.004
- 371 [14] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates o
372 f Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,
373 2021,71(3):209-249.DOI: 10.3322/caac.21660
- 374 [15] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mo
375 rtality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953.
376 DOI: 10.1002/ijc.31937
- 377 [16] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Natu
378 re, 2000,406(6797):747-752.DOI: 10.1038/35021093

- 379 [17] Bian X W, Jiang X F, Chen J H, et al. Increased angiogenic capabilities of endothelial cells
380 from microvessels of malignant human gliomas[J]. *Int Immunopharmacol*, 2006,6(1):90-99.DOI:
381 I: 10.1016/j.intimp.2005.08.004
- 382 [18] Claudon M, Dietrich C F, Choi B I, et al. Guidelines and good clinical practice recommendat
383 ions for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB
384 initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS
385 [J]. *Ultraschall Med*, 2013,34(1):11-29.DOI: 10.1055/s-0032-1325499
- 386 [19] Wang X Y, Kang L K, Lan C Y et al. Characteristics and diagnosis of breast malignant ma
387 sses by contrast-enhanced ultrasound[J]. *Chinese Journal of Ultrasonography*, 2012,28(08):705
388 -708
- 389 [20] He J. The application value of contrast-enhanced ultrasound in the diagnosis of breast tumors
390 [J]. *Journal of Clinical Ultrasound in Medicine*, 2017,19(7):471-473
- 391 [21] Lin Y. *Journal of Clinical Ultrasound in Medicine*[D]. Guangxi Medical University, 2014.
- 392 [22] Jia W R. Study on contrast-enhanced ultrasound based on different molecular subtypes of bre
393 ast cancer[D]. Shanghai Jiao Tong University, 2015.
- 394 [23] Wang B T. The application value of serum tumor markers combined with dynamic detection
395 in the diagnosis and monitoring of breast cancer[D]. Qingdao University, 2021.
- 396 [24] Ghadge M S, Naik P P, Tiwari B P, et al. A Comparative Study of Bone Scan Findings and
397 Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma[J]. *Indian J Clin*
398 *Biochem*, 2012,27(1):97-99.DOI: 10.1007/s12291-011-0168-5
- 399 [25] Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a
400 new biomarker panel for breast cancer[J]. *Int J Mol Sci*, 2014,15(6):9546-9565.DOI: 10.3390
401 /ijms15069546
- 402











